Gary Maartens

Q: What Schools Are Affiliated With Gary Maartens

Gary Maartens is affiliated with the following schools: University of the Western Cape, University of Cape Town

Gary Maartens's AcademicInfluence.com Rankings

Gary Maartens

Biology

#10515

World Rank

#13848

Historical Rank

Genetics

#1113

World Rank

#1212

Historical Rank

Molecular Biology

#1538

World Rank

#1565

Historical Rank

biology Degrees

Download Badge

Biology

Gary Maartens's Degrees

Bachelors Biochemistry University of Cape Town
Masters Molecular Biology University of Cape Town
PhD Genetics University of Cape Town

Why Is Gary Maartens Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gary Maartens's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

HIV infection: epidemiology, pathogenesis, treatment, and prevention (2014) (690)
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. (2008) (660)
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa (2004) (650)
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. (2017) (447)
Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa (2009) (421)
Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies (2011) (391)
Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes (2007) (380)
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (2010) (327)
Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults (2006) (304)
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa (2010) (288)
Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. (1990) (284)
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. (2005) (258)
Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa (2020) (255)
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. (2007) (251)
Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. (2007) (229)
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial (2014) (224)
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. (2008) (216)
Treatment Supporter to Improve Adherence to Antiretroviral Therapy in HIV-Infected South African Adults: A Qualitative Study (2006) (210)
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa: Implications for Prophylaxis and Treatment (2006) (193)
Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy (2008) (186)
Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. (2009) (177)
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. (2018) (173)
Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. (2001) (167)
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. (2007) (164)
Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa (2005) (154)
Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. (2008) (149)
Hypercytokinaemia accompanies HIV–tuberculosis immune reconstitution inflammatory syndrome (2010) (146)
Concurrent infections and HIV pathogenesis (2000) (143)
Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. (1998) (136)
Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. (2015) (133)
The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications (2011) (126)
Risk Factors for Developing Tuberculosis in HIV‐1‐Infected Adults From Communities With a Low or Very High Incidence of Tuberculosis (2000) (125)
When to Initiate Highly Active Antiretroviral Therapy in Sub-Saharan Africa? A South African Cost-Effectiveness Study (2006) (117)
Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. (2008) (117)
Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. (2009) (116)
Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With Tuberculosis (2008) (113)
Prednisone for the Prevention of Paradoxical Tuberculosis‐Associated IRIS (2018) (111)
Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting (2011) (110)
Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry (2006) (108)
CD4 and total lymphocyte counts as predictors of HIV disease progression. (1996) (106)
Factors Influencing Retention in Care after Starting Antiretroviral Therapy in a Rural South African Programme (2011) (106)
Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: A cross-sectional study (2008) (105)
Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations (2001) (105)
Tuberculous pleural effusions: increased culture yield with bedside inoculation of pleural fluid and poor diagnostic value of adenosine deaminase. (1991) (104)
Tuberculosis (1936) (104)
A comparative study of the polymerase chain reaction and conventional procedures for the diagnosis of tuberculous pleural effusion. (1992) (102)
Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction (2013) (99)
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. (2007) (97)
Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing (2008) (97)
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa (2008) (95)
Neuronal toxicity of efavirenz: a systematic review (2013) (94)
Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy (2010) (93)
Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. (2007) (92)
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults (2008) (86)
Effect of Nonnucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy on Dysglycemia and Insulin Sensitivity in South African HIV-Infected Patients (2011) (85)
Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. (2006) (85)
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. (2020) (84)
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. (2019) (81)
A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy (2015) (81)
Guidelines for antiretroviral therapy in adults (2012) (79)
Performance of Serum C-Reactive Protein as a Screening Test for Smear-Negative Tuberculosis in an Ambulatory High HIV Prevalence Population (2011) (78)
Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections (2009) (78)
HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling (2015) (78)
Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. (2012) (77)
Association of Antiretroviral Therapy Adherence and Health Care Costs (2010) (77)
Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis (2009) (75)
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen (2018) (75)
Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. (2015) (74)
High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children (2007) (74)
Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection (2016) (73)
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. (2015) (71)
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. (2009) (70)
Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. (2004) (70)
Effectiveness and Safety of Antiretrovirals with Rifampicin: Crucial Issues for High-Burden Countries (2009) (69)
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole (2006) (66)
The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. (2011) (65)
Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients (2011) (64)
Handbook of HIV Medicine (2008) (62)
Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (2000) (62)
Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations (2015) (61)
Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index (2016) (60)
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis (2009) (60)
Diagnosing HIV-associated tuberculosis: reducing costs and diagnostic delay. (2000) (58)
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype (2013) (56)
Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis (2011) (56)
Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: Importance of Cavities, Smoking, Time to Detection and W-Beijing Genotype (2012) (56)
Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets (2011) (55)
Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. (2012) (55)
Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes? (2017) (54)
Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy (2016) (52)
Plasma vitamin A and zinc levels in HIV-infected adults in Cape Town, South Africa (2003) (51)
Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients : guideline (2007) (50)
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. (2016) (49)
South African guideline for the management of community-acquired pneumonia in adults. (2017) (48)
Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. (2000) (47)
Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients (2016) (46)
Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study (2019) (45)
Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome (2013) (45)
CheXaid: deep learning assistance for physician diagnosis of tuberculosis using chest x-rays in patients with HIV (2020) (45)
Adverse Drug Reactions Causing Admission to Medical Wards (2016) (43)
The clinical presentation and diagnosis of invasive fungal infections. (1991) (42)
Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa. (2014) (41)
Is it safe to switch between efavirenz and nevirapine in the event of toxicity? (2007) (40)
Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans (2015) (38)
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. (2019) (38)
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz (2020) (38)
Effect of different antiretroviral drug regimens on body fat distribution of HIV-infected South African women. (2013) (37)
A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture (2012) (37)
Independent epidemics of heterosexual and homosexual HIV infection in South Africa--survival differences. (1997) (37)
Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study (2017) (36)
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. (2021) (36)
Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. (2016) (35)
The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy (2012) (35)
Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women (2015) (35)
Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. (2013) (35)
HIV Infection Is Associated with a Lower Incidence of Constriction in Presumed Tuberculous Pericarditis: A Prospective Observational Study (2008) (35)
Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. (2011) (34)
Opportunistic infections associated with HIV infection in Africa. (2002) (34)
Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms (2011) (33)
Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence. (2002) (33)
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. (2017) (32)
Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study (2015) (32)
Drug induced kidney disease (2011) (32)
Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. (2007) (32)
Role of the Interleukin 10 Family of Cytokines in Patients With Immune Reconstitution Inflammatory Syndrome Associated With HIV Infection and Tuberculosis (2013) (32)
Vertical HIV transmission in South Africa: translating research into policy and practice (2002) (31)
Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study (2015) (30)
Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes (2018) (30)
Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations (2016) (29)
Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system (2017) (29)
Cytotoxic Mediators in Paradoxical HIV–Tuberculosis Immune Reconstitution Inflammatory Syndrome (2015) (29)
Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. (2014) (29)
Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. (2012) (29)
Guidelines for antiretroviral therapy in adults by the Southern African HIV clinicians society (2012) (29)
Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study (2014) (28)
Guidelines for the management of acute meningitis in children and adults in South Africa (2013) (28)
Systematic review of the evidence for rational dosing of colistin. (2014) (27)
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings (2017) (27)
Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen (2016) (27)
Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps (2017) (27)
Strengthening pharmacovigilance in South Africa. (2013) (27)
Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus–Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization Algorithm (2018) (27)
Management of active tuberculosis in adults with HIV. (2019) (26)
Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids. (2007) (26)
Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update (2020) (25)
Diagnostic yield of peripheral lymph node needle-core biopsies in HIV-infected adults with suspected smear-negative tuberculosis. (2005) (25)
Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors (2010) (25)
Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy (2016) (25)
Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa (2019) (24)
Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. (2019) (24)
C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study (2018) (24)
The costs and perceived quality of care for people living with HIV / AIDS in the Western Cape Province in South Africa. (2000) (24)
Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital). (2009) (24)
AIDS in Africa--survival according to AIDS-defining illness. (2001) (24)
The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. (2004) (24)
Guideline for the management of upper respiratory tract infections. (2004) (24)
The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries (2018) (24)
Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study (2016) (23)
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. (2021) (23)
Discovery of "false Elite Controllers": HIV antibody-positive RNA-negative blood donors found to be on antiretroviral treatment. (2019) (23)
Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa? (2011) (23)
A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis (2019) (23)
Inequality in outcomes for adolescents living with perinatally acquired HIV in sub‐Saharan Africa: a Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration analysis (2018) (23)
The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients (2015) (23)
Cytolytic T‐cell Activity Against Mycobacterial Antigens in HIV (1992) (22)
Management of community-acquired pneumonia in adults (2007) (22)
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children (2010) (22)
Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy (2015) (22)
Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV (2018) (21)
Complications of Antiretroviral Therapy Initiation in Hospitalised Patients with HIV-Associated Tuberculosis (2013) (21)
Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data (2020) (21)
Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases (2019) (21)
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. (2012) (20)
Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. (2014) (20)
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. (2021) (20)
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children (2010) (20)
Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis (2019) (20)
Decentralization of HIV care in St. Petersburg Russia. (2009) (20)
Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV‐positive individuals (2017) (20)
A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. (2019) (20)
Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. (2016) (20)
Clofazimine pharmacokinetics in patients with TB: dosing implications (2020) (19)
Moderate to severe HIV-associated neurocognitive impairment (2016) (18)
Mortality in Severe Human Immunodeficiency Virus-Tuberculosis Associates With Innate Immune Activation and Dysfunction of Monocytes (2017) (18)
Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. (2018) (18)
'Atypical' bacteria are a common cause of community-acquired pneumonia in hospitalised adults. (1994) (18)
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection (2019) (18)
Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update (2015) (18)
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? (2010) (18)
Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study. (2013) (18)
Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. (2016) (17)
A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa (2013) (17)
Updated recommendations for the management of upper respiratory tract infections in South Africa. (2015) (17)
Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements (2018) (17)
Tuberculosis (2007) (17)
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy A Case Series (2017) (16)
Tuberculosis in the tropics. (2002) (15)
Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence (2012) (15)
Predictors and prognostic value of oral hairy leukoplakia and oral candidiasis in South African HIV-infected patients. (2001) (15)
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study (2021) (15)
Advances in adult pulmonary tuberculosis. (2002) (15)
Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. (2016) (15)
The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings (2014) (15)
Early severe morbidity and resource utilization in South African adults on antiretroviral therapy (2009) (15)
The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children (2017) (15)
Severe antiretroviral‐associated skin reactions in South African patients: a case series and case–control analysis (2016) (15)
Quantitative and Functional Differences between Peripheral Blood Myeloid Dendritic Cells from Patients with Pleural and Parenchymal Lung Tuberculosis (2006) (15)
Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. (2018) (14)
Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection (2019) (14)
A Randomized Controlled Trial of Intravenous N-acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. (2020) (14)
Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases (2011) (14)
The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting (2019) (14)
Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study (2021) (14)
Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings (2010) (14)
Antibiotic resistance in community-acquired urinary tract infections. (1994) (14)
Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors (2016) (13)
Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial (2021) (13)
Co-trimoxazole in HIV-1 infection (1999) (13)
Course and complications of varicella zoster ophthalmicus in a high HIV seroprevalence population (Cape Town, South Africa) (2009) (13)
Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis (2018) (13)
Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa (2016) (13)
Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis (2021) (13)
CheXaid: deep learning assistance for physician diagnosis of tuberculosis using chest x-rays in patients with HIV. (2020) (13)
A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive protein. (2012) (12)
Increased Mortality with Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. (2020) (12)
T-lymphocyte responses to Pneumocystis carinii in healthy and HIV-positive individuals. (1992) (12)
Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data (2020) (12)
Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites (2018) (12)
Pneumocystis carinii pneumonia in HIV-infected patients in Africa--an important pathogen? (2000) (11)
Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. (2015) (11)
The treatment gap for mental disorders in adults enrolled in HIV treatment programmes in South Africa: a cohort study using linked electronic health records (2020) (11)
Substitutions Due to Antiretroviral Toxicity or Contraindication in the First 3 years of Antiretroviral Therapy in a Large South African Cohort (2007) (10)
Is HIV/AIDS a primary‐care disease? Appropriate levels of outpatient care for patients with HIV/AIDS (1995) (10)
Linezolid for Treating Tuberculosis: A Delicate Balancing Act (2015) (10)
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. (2013) (10)
Plasma Lopinavir Concentrations Predict Virological Failure in a Cohort of South African Children Initiating a Protease-Inhibitor-Based Regimen (2014) (10)
Etiology of Pulmonary Infections in Human Immunodeficiency Virus–infected Inpatients Using Sputum Multiplex Real-time Polymerase Chain Reaction (2019) (9)
Pitfalls of administering drugs via nasogastric tubes. (2009) (9)
Building on the first decade of ART (2014) (9)
Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial) (2016) (9)
Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study (2010) (9)
CD4 T-cell responses to combination antiretroviral therapy (2007) (9)
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. (2020) (9)
Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports (2016) (9)
Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis (2021) (8)
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study (2022) (8)
Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn? (2020) (8)
Drug interactions with antiretroviral therapy : drug interactions (2002) (8)
Cerebral angioedema associated with enalapril. (2009) (8)
Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1 (2018) (8)
Selected questions and controversies about bedaquiline: a view from the field. (2016) (8)
Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis (2021) (7)
Drug-induced renal injury: The kidney plays an important role in the elimination of many drugs and their metabolites (2011) (7)
Clinical aspects of tuberculosis in HIV-infected adults (2009) (7)
Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting (2019) (7)
Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis. (2019) (7)
Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone (2020) (7)
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis (2022) (7)
A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy (2019) (7)
Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial (2017) (7)
Clinical progression of HIV infection in adults. (1999) (7)
Abdominal Ultrasound for the Diagnosis of Tuberculosis Among Human Immunodeficiency Virus-Positive Inpatients With World Health Organization Danger Signs (2019) (7)
Diagnostic Accuracy and Clinical Role of Rapid C-Reactive Protein Testing in HIV-infected TB Suspects in South Africa (2014) (7)
An All-Oral 6-Month Regimen for Multidrug-Resistant TB (the NExT Study): A Multicenter, Randomized Controlled Trial. (2022) (7)
Adult antiretroviral therapy guidelines 2014 By the Southern African HIV Clinicians Society (2014) (6)
Lower-dose efavirenz: what is needed before implementation? (2015) (6)
Brief Report: Real-World Performance and Interobserver Agreement of Urine Lipoarabinomannan in Diagnosing HIV-Associated Tuberculosis in an Emergency Center (2019) (6)
Development of a clinical prediction rule to diagnose Pneumocystis jirovecii pneumonia in the World Health Organization’s algorithm for seriously ill HIV-infected patients (2018) (6)
Undisclosed HIV status and antiretroviral therapy use among South African blood donors (2021) (6)
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis (2020) (6)
Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir. (2016) (6)
Plasma biomarkers to detect prevalent, or predict progressive, HIV-1-associated tuberculosis. (2018) (6)
Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis (2021) (6)
First-line antiretroviral drug discontinuations in children (2017) (6)
A Clinical Prediction Score Including Trial of Antibiotics and C-Reactive Protein to Improve the Diagnosis of Tuberculosis in Ambulatory People With HIV (2020) (6)
The role of the infectious diseases unit at Groote Schuur Hospital in addressing South Africa's greatest burden of disease. (2012) (6)
Anthropometric definitions for antiretroviral-associated lipodystrophy derived from a longitudinal South African cohort with serial dual-energy X-ray absorptiometry measurements (2018) (5)
South African guideline for the management of community-acquired pneumonia in adults (2018) (5)
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis? (2020) (5)
Resistance matters in EARNEST. (2017) (5)
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy (2020) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
The spectrum and prognosis of AIDS-defining illnesses in Cape Town (2005) (5)
Adult antiretroviral therapy guidelines 2014 : guideline (2014) (5)
Drug-induced haemolytic anaemia (2007) (5)
Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis (2021) (5)
Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial (2021) (5)
Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study (2022) (4)
Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study (2012) (4)
Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans (2019) (4)
Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts (2018) (4)
Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics (2020) (4)
Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis (2019) (4)
Emtricitabine-associated red cell aplasia. (2019) (4)
A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis (2021) (4)
The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. (2015) (4)
Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study (2017) (4)
Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] (2021) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Erratum: HIV infection: Epidemiology, pathogenesis, treatment, and prevention (Lancet (2014) 384 (258-71)) (2014) (4)
Pharmacology of anthelmintics : albendazole, mebendazole and praziquantel : clinical pharmacology (2009) (4)
Changes in Body Fat Distribution on Dual-Energy X-Ray Absorptiometry in Black South Africans Starting First-Line Antiretroviral Therapy. (2016) (4)
Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy (2021) (4)
Clinical pharmacology becomes a specialty in South Africa. (2013) (4)
Guideline: Management of community-acquired pneumonia in adults (2008) (3)
Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients (2021) (3)
Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials (2022) (3)
No evidence for naturally occurring mutations resistant to HIV-1 reverse-transcriptase inhibitors among South African HIV-1 subtype C isolates (2000) (3)
Diagnosis and treatment of opioid use disorder in a South African private sector medical insurance scheme: a cohort study (2022) (3)
Essential medicine selection during the COVID-19 pandemic: Enabling access in uncharted territory. (2020) (3)
Initiating antiretroviral therapy (2005) (3)
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children (2016) (3)
Diagnostic Accuracy of the INSHI Consensus Case Definition for the Diagnosis of Paradoxical Tuberculosis-IRIS (2020) (3)
Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study (2022) (3)
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens (2022) (3)
The prevention and treatment of opportunistic infections in HIV-infected adults. (2002) (3)
Safety and Effectiveness of Isoniazid Preventive Therapy in HIV-Positive Pregnant Women on Art: An Observational Study using Linked Population Data. (2020) (3)
A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre (2020) (3)
Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis (2021) (3)
Occupational post-exposure HIV prophylaxis. (2004) (3)
Dosing of raltegravir when given with rifampicin. (2014) (3)
Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults? (2012) (3)
CO-TRIMOXAZOLE IN HIV-1 INFECTION. AUTHORS' REPLY (1999) (3)
The immune-compromised traveller (2008) (3)
Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. (2022) (3)
Emtricitabine-associated red cell aplasia. (2019) (3)
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens (2021) (2)
Correction to: Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis (2020) (2)
Antiretroviral therapy and drug interactions. (2001) (2)
Tuberculosis preventive therapy in HIV infection (2001) (2)
Diagnostic Outcomes After Chest Radiograph Interpretation in Patients With Suspected Tuberculosis and Negative Sputum Smears in a High-Burden Human Immunodeficiency Virus and Tuberculosis Setting (2017) (2)
The cost of adult AIDS inpatient care. (1994) (2)
Point-of-Care Ultrasound Predictors for the Diagnosis of Tuberculosis in HIV-Positive Patients Presenting to an Emergency Center. (2020) (2)
Guidelines for tuberculosis preventive therapy in HIV infection. Consensus guidelines from a workshop, 29-30 October 1999. HIV Clinicians Society of Southern Africa. (2000) (2)
Antiviral therapy in herpesvirus infections (2003) (2)
Programmatic review of safety and effectiveness of isoniazid preventive therapy in HIV-infected pregnant women on ART in routine care (2018) (2)
Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. (2016) (2)
Impact of HIV on admissions and deaths in a tuberculosis hospital--recommendations for admission and discharge criteria. (2003) (2)
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid (2021) (2)
Deciding when to institute terminal palliative care for AIDS patients--an evidence-based approach. (2001) (2)
0223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children (2010) (2)
Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis (2018) (2)
Adult medical emergency unit presentations due to adverse drug reactions in a setting of high HIV prevalence (2020) (2)
Drug interactions with the calcium-channel blockers (2008) (2)
HIV and sexual assault. (1999) (2)
Global HIV/AIDS Clinical and Translational Pharmacology (2012) (2)
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). (2022) (2)
HIV/AIDS in South Africa: Prevention of opportunistic infections in adults (2010) (2)
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals [Short communication]. (2013) (2)
An All-Oral 6-Month Regimen for Multi-Drug Resistant/Rifampicin-Resistant Tuberculosis: A Multi-Centre, Phase 3, Open Label, Randomised Controlled Trial (NeXT Study) (2021) (1)
Response to the communication of M Hosp et al. on low‐cost progression markers in HIV‐1 seropositive Zambians (2001) (1)
Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment (2022) (1)
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin (2022) (1)
Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort (2022) (1)
Treatment of Drug-Sensitive Tuberculosis in Persons with HIV (2019) (1)
Building on the first decade of ART : reflections (2014) (1)
Common parasitic infections in the HIV-infected patient (2009) (1)
Ruling opens door for coverage of prescription contraceptives. (2001) (1)
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial (2022) (1)
Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis (2020) (1)
Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa". (2007) (1)
Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment (2022) (1)
Managemetn of HIV and tuberculosis co-infection in South Africa (2004) (1)
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial (2022) (1)
Syncope in the elderly. Report of 3 cases with sick sinus syndrome. (1986) (1)
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline (2022) (1)
Pharmacology of anthelminitics: albendazole, mebendazole and praziquantel (2009) (1)
Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model (2022) (1)
Prevention of TB in HIV. (1992) (1)
Remdesivir for COVID‐19: evidence review of the clinical benefit and harm (2020) (1)
A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre. (2020) (1)
Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine (2019) (1)
Unrecognised Mycobacterium tuberculosis (2000) (1)
The effect of the COVID-19 lockdown on mental health care use in South Africa: an interrupted time-series analysis (2022) (1)
The mother-to-child HIV transmission debate. (1999) (1)
Interactions between HIV and hepatitis B and C (2003) (1)
Treatment of syphilis in HIV-infected individuals--more questions than answers? (1994) (1)
Simultaneous Determination of Carvedilol, Enalaprilat, and Perindoprilat in Human Plasma Using LC–MS/MS and Its Application to a Pharmacokinetic Pilot Study (2022) (1)
Acute disseminated encephalomyelitis due to Rickettsia conorii infection. (2021) (1)
Erratum to South African guideline for the management of community-acquired pneumonia in adults. (2018) (1)
Dolutegravir drug-drug interactions (2022) (1)
Analysis of serum microRNA-122 in a randomised controlled trial of N-acetylcysteine for treatment of anti-tuberculosis drug-induced liver injury. (2023) (1)
Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa. (2019) (1)
Generic substitution--is it safe in patients at high cardiovascular risk? (2002) (1)
Azithromycin for COVID‐19: evidence review of the clinical benefit and harm (2020) (1)
Antiretroviral treatment protocol Provincial Administration Western Cape (based on national treatment guidelines). Version 1. (2003) (1)
Antibiotic prescribing in respiratory tract infections: first do no harm (2008) (1)
‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy (2020) (1)
Dolutegravir for second-line treatment: Programmatic implications of new evidence (2022) (0)
Guideline for the prevention and m anagem ent of nosocom ial infections in South Africa (2005) (0)
Cancer treatment and survival among cervical cancer patients living with or without HIV in South Africa (2022) (0)
Mental health, longitudinal ART adherence, and viral suppression among adolescents and adults living with HIV in South Africa: a cohort study (2022) (0)
Xpert-Ultra to Detect and Quantify HIV-Associated Mycobacterium tuberculosis Blood Stream Infection: A Cohort Study (2021) (0)
Iqbal Haroon Master (2021) (0)
Favipiravir for the prevention and management of COVID‐19: evidence review of the clinical benefit and harm (2020) (0)
Gary Maartens--committed to improving public health in South Africa. (2002) (0)
Chapter 93 – Deteriorating tuberculosis in a HIV-infected man despite treatment: Immune reconstitution, resistance, or drug malabsorption? (2009) (0)
The impact of enteral feeding and therapeutic monitoring of rifampicin with dose-escalation in critically ill patients with tuberculosis. (2022) (0)
RESEARCH DAY PROGRAMME - 2007 (2007) (0)
Antiviral therapy in herpes virus infections (2003) (0)
Chloroquine and hydroxychloroquine for prevention of COVID‐19: evidence review of clinical benefits and harm (2020) (0)
Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis (2019) (0)
Mycobacterium Tuberculosis Blood Stream Infection Prevalence, Diagnosis, and Mortality Hazard in HIV-Positive Adults: A Systematic Review and Meta-Analysis of Individual Patient Data (2019) (0)
Therapeutic challenges : interactions between anticonvulsants and antiretrovirals : clinical pharmacology (2006) (0)
Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV (2023) (0)
The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study (2022) (0)
Antiretroviral therapeutic drug monitoring (2006) (0)
Low cost prognostic indicators of HIV infection (2001) (0)
Life-years lost associated with mental illness: a cohort study of beneficiaries of a South African medical insurance scheme (2023) (0)
Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a non-comparative, double-blind, randomised placebo-controlled trial. (2023) (0)
POSTER SESSION POSTER SESSION BOOK OF ABSTRACTS Faculty of Pharmacy 50 Years (2018) (0)
A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis (2023) (0)
Diagnosis and treatment of pulmonary tuberculosis in patients with HIV. (2012) (0)
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial (2021) (0)
Evidence-based Infectious Diseases, edited by Mark Loeb, Marek Smieja and Fiona Small : book review (2005) (0)
TabletsAdjusted Doses of Lopinavir-Ritonavir HIV-Infected Adults Receiving Rifampin Pharmacokinetics of Lopinavir in (2014) (0)
The immune-compromised traveller : main topic (2005) (0)
12 HIV infection and AIDS (2019) (0)
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. (2023) (0)
Focused investigations to expedite cancer diagnosis among patients with lymphadenopathy in a tuberculosis and HIV-endemic region (2022) (0)
Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks (2022) (0)
General Approach to the Patient (2003) (0)
FULL Increased Mortality with Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa Mortality after Delayed or Missed ART Switch in South Africa (2021) (0)
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study (2022) (0)
AIDS review. Antiretroviral therapy and drug interactions. (2001) (0)
ART and tuberculosis: the final nail in nevirapine's coffin? (2013) (0)
Tuberculous pleural effusions : a prospective study of rapid diagnostic tests (adenosine deaminase, antigen capture enzyme-linked immunosorbent assay, and the polymerase chain reaction) and evaluation of a radiometric mycobacterial culture system (1990) (0)
Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay (2022) (0)
Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: A qualitative study. (2023) (0)
Ritonavir‐boosted protease inhibitor‐containing regimens versus non‐boosted protease‐inhibitor‐containing regimens for reducing morbidity and mortality in people with HIV/AIDS (2005) (0)
Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV (2022) (0)
Erratum for Banda et al., “Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV” (2023) (0)
Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment (2022) (0)
sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies (2023) (0)
The downside of success: confi rmation of HIV infection in early treated children (2015) (0)
Using antiretroviral therapy in patients with tuberculosis : TB and ART (2002) (0)
Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm (2020) (0)
The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting (2019) (0)
Therapeutic challenges: interactions between anticonvulsants and antiretrovirals (2008) (0)
Pre-exposure prophylaxis to intensify the fight against HIV (2014) (0)
Diagnostic accuracy of WHO screening criteria to guide lateral-flow lipoarabinomannan testing among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. (2022) (0)
Reply to author. (2020) (0)
Case Report: Tumour lysis syndrome (2012) (0)
Department of Error (2014) (0)
Pharmacogenetics of Efavirenz: Adherence and Virologic Outcomes (2007) (0)
Diagnostic Yield of Urine Lipoarabinomannan and Sputum Tuberculosis Tests in People Living with HIV: A Systematic Review and Meta-Analysis of Individual Participant Data (2022) (0)
A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. (2022) (0)
Predictors of Tuberculosis Mortality in a High HIV Prevalent Setting (2012) (0)
Tuberculosis in developing countries. Highlights of TB research in developing countries presented at the XIIIth International AIDS Conference. (2000) (0)
Title : A treatment recommender clinical decision support system for personalized medicine : 1 method development and proof-of-concept for drug resistant tuberculosis 2 (2021) (0)
Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling (2023) (0)
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. (2023) (0)
Lopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harms (2020) (0)
Antiviral therapy in herpesvirus infections : main topic (2003) (0)
Associated with Reduced Rifampicin Concentrations: Dosing Implications (2011) (0)
Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults? [Perspectives]. (2012) (0)
Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. (2022) (0)
Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV (2022) (0)
Drug-drug interactions involving second generation NNRTIs (2016) (0)
Guidelines for the Management of Sexually Transmitted Infections, WHO : book review (2005) (0)
Pharmacokinetic and Pharmacogenetic Associations with Dolutegravir Neuropsychiatric Adverse Events in an African Population (2022) (0)
Immunity to mycobacterial infection (PP-061) (2010) (0)
Routine HIV testing before surgery. (1992) (0)
Drug-induced haemolytic anaemia : clinical pharmacology (2007) (0)
Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction. (2023) (0)
Why don't patients use medication as prescribed? (2008) (0)
3rd SA HIV Conference, Durban - track summaries : conference report (2007) (0)
Routine Antiretroviral Pharmacy Refill Information Can Predict Failure Postpartum in Previously Suppressed South African Women With HIV. (2022) (0)
Prolonged HIV infection without disease progression. (1996) (0)
Cerebrospinal Fluid and Tuberculosis Meningitis. (2023) (0)
Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations (2019) (0)
Managing HIV-associated tuberculosis in the dolutegravir era. (2019) (0)
Using antiretroviral therapy in patients with tuberculosis (2002) (0)
Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV (2022) (0)
The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries (2018) (0)
Clofazimine for the treatment of tuberculosis (2023) (0)
Treatment Outcomes 24 Months after Initiating Short Bedaquiline- or Injectable-Containing Rifampicin-Resistant Tuberculosis Treatment Regimens: A Retrospective Cohort Study in South Africa (2021) (0)
Interactions between HIV and hepatitis B or C (2008) (0)
Coadministration of antitubercular and antiretroviral therapy is common in high-burden countries where tuber- (2009) (0)
Drug-drug interactions in oncology: implications for general practice (2007) (0)
In reply to 'Serum C-reactive protein measurement for ruling out HIV-associated tuberculosis'. (2013) (0)
Mental Health, ART Adherence, and Viral Suppression Among Adolescents and Adults Living with HIV in South Africa: A Cohort Study (2023) (0)
Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis (2022) (0)
MALARIA CHEMOPROPHYLAXIS. REPLIES (1993) (0)
Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS. Reply. (2019) (0)
In memory of Dr Steve Andrews (1970 - 2009) : tribute (2009) (0)
Tumour lysis syndrome : case report (2012) (0)
Corticosteroids for COVID‐19: evidence review of the ckinical benefit and harm (2020) (0)
Track B Clinical Science (2012) (0)
Pharmacogenetics of dolutegravir plasma exposure among Southern Africans living with HIV (2022) (0)
Antiretroviral therapeutic drug monitoring : laboratory (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gary Maartens?

Gary Maartens is affiliated with the following schools:

Gary Maartens's Academic­Influence.com Rankings

Gary Maartens's Degrees

Why Is Gary Maartens Influential?

Gary Maartens's Published Works

Published Works

What Schools Are Affiliated With Gary Maartens?

Gary Maartens's AcademicInfluence.com Rankings